Share on LinkedInShare on LinkedIn

ARTICLE · 28 AUGUST 2025

Navigating The Patenting Of Antibodies In China: A Guide Based On Current CNIPA Practice

Monoclonal antibodies remain one of the most commercially valuable classes of biologics, yet obtaining robust patent protection for them in China requires a precise understanding of the China...

ChinaIntellectual Property

Introduction

Monoclonal antibodies remain one of the most commercially valuable classes of biologics, yet obtaining robust patent protection for them in China requires a precise understanding of the China National Intellectual Property Administration's (CNIPA) evolving examination standards. This article aims to clarify how claims must be drafted, how novelty and inventiveness are assessed, and which formalities must be observed for applications relating to antibodies. Below is a concise roadmap that reflects CNIPA's current practice into practical advice for companies, universities, and patent attorneys.

  1. Claim Language – Two Acceptable Paths

CNIPA accepts two alternative formats for antibody claims, i.e. the antibody can be defined by its structure or the hybridoma which produces the antibody. The applicant could choose the one that best aligns with the available experimental data.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

AFD China Newsletter is intended to provide our clients and business partners information only. The information provided on the newsletter should not be considered as professional advice, and should not form the basis of any business decisions.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from